Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19774557 | 0.88 | TSHR (0.61) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12847428 | 0.80 | TSHR (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL28973808 | 0.80 | TSHR (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10052366 | 0.78 | TSHR (0.54) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL13003073 | 0.78 | TSHR (0.54) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9066577 | 0.77 | TACR1 (0.57) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL997580 | 0.77 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL2717725 | 0.77 | CA1 (0.68) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL19726048 | 0.77 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL17789132 | 0.77 | TSHR (0.52) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046939-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9127033-B2 | 5′ modified nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20130116420-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116420-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NSUN2 | TSHR 4367/4885CA1 4701/4885CA2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.